{"id":"W4392853633","doi":"10.1136/lupus-2024-el.42","title":"O33 Longitudinal assessment of biomarkers in NOBILITY, a randomized, phase II clinical trial of obinutuzumab for treatment of proliferative lupus nephritis","year":2024,"lang":"en","type":"article","venue":"Oral Presentations","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche; AstraZeneca; Bristol-Myers Squibb","keywords":"Obinutuzumab; Lupus nephritis; Medicine; Internal medicine; Oncology; Disease; Rituximab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001758295,0.0008294434,0.0008859302,0.0001944314,0.0003983737,0.0007718432,0.0004201595,0.001168248,0.003968027],"category_scores_gemma":[0.001116963,0.0003278911,0.000859081,0.0001565459,0.0006698987,0.0005315142,0.0002894038,0.001549817,0.0004975311],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004820091,"about_ca_system_score_gemma":0.001254632,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000629377,"about_ca_topic_score_gemma":0.002329346,"domain_scores_codex":[0.9994987,0.000298235,0.00001629692,0.00005663352,0.00004757097,0.00008252798],"domain_scores_gemma":[0.999129,0.0001274409,0.0002454644,0.00006215036,0.00005476627,0.0003811523],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9311762,0.01887324,0.004666564,0.0004576948,0.0005530972,0.000108684,0.00009133431,0.0003067053,0.01576701,0.0001620607,0.002312381,0.02552499],"study_design_scores_gemma":[0.7973042,0.1886711,0.009686839,0.00003620297,0.0003005698,0.00008347702,0.0000254769,0.0004188278,0.001754569,0.0001845587,0.001516836,0.00001738446],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935117,0.001408508,0.0002641218,0.0004100929,0.0001691539,0.00181897,0.0007163606,0.00006682179,0.001634155],"genre_scores_gemma":[0.9921897,0.0006417534,0.0008198674,0.000957644,0.0002403368,0.001624867,0.0008952601,0.00001581813,0.002614668],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003968027,"threshold_uncertainty_score":0.01327437,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1512239871831306,"score_gpt":0.5173853706958021,"score_spread":0.3661613835126716,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}